- Home
- RDZN vs SGMT Comparison
RDZN vs SGMT Comparison
Compare RDZN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RDZN | SGMT |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.7M | 164.6M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | RDZN | SGMT |
|---|---|---|
| Price | $1.17 | $5.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 197.5K | ★ 827.1K |
| Earning Date | 02-12-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,304,685.00 | N/A |
| Revenue This Year | $40.39 | N/A |
| Revenue Next Year | $64.09 | $125.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.28 | N/A |
| 52 Week Low | $0.68 | $1.73 |
| 52 Week High | $2.56 | $11.41 |
Technical Indicators
Market Signals| Indicator | RDZN | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 24.97 | 37.97 |
| Support Level | $1.65 | $5.04 |
| Resistance Level | $1.62 | $5.74 |
| Average True Range (ATR) | 0.14 | 0.49 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 20.93 | 4.35 |
Price Performance
Historical ComparisonAbout RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.